Cargando…
Genetic abnormalities in pancreatic cancer
The incidence and mortality of pancreatic adenocarcinoma are nearly coincident having a five-year survival of less than 5%. Enormous advances have been made in our knowledge of the molecular alterations commonly present in ductal cancer and other pancreatic malignancies. One significant outcome of t...
Autores principales: | Moore, Patrick S, Beghelli, Stefania, Zamboni, Giuseppe, Scarpa, Aldo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC149421/ https://www.ncbi.nlm.nih.gov/pubmed/12537585 http://dx.doi.org/10.1186/1476-4598-2-7 |
Ejemplares similares
-
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models
por: Capello, Michela, et al.
Publicado: (2013) -
Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium
por: Mafficini, Andrea, et al.
Publicado: (2018) -
A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007) -
Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer
por: Bauer, Andrea S., et al.
Publicado: (2017) -
Irrelevance of Microsatellite Instability in the Epidemiology of Sporadic Pancreatic Ductal Adenocarcinoma
por: Laghi, Luigi, et al.
Publicado: (2012)